Companies: 10,795·Total market cap: $144.5T
Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc.

FULCNASDAQHealthcare● Active
$3.52
+$0.08(+2.18%)
Market Cap$190201494
P/E Ratio—
52W High$15.74
52W Low$2.83
Shares OutstandingFinancialsRevenue

Fulcrum Therapeutics, Inc. (FULC) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

FULC · shares outstanding · updated Jun 9, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
63.4M▲ +2.21% YoY Change
FY · as of Dec 31, 2025 · Reported in USD
vs 62.0M in FY 2024
Diluted Shares Outstanding
63.4M
incl. options, RSUs, convertibles
Dilution Spread
+0.00%
Diluted vs Basic
YoY Change
+2.21%
year-over-year
Float (Free Float)
48.0M
publicly tradable shares
88.7% of total
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-09

Shares Outstanding Growth Rate

3-Year CAGRincreasing
+12.1%
2022 → 2025
5-Year CAGRincreasing
+20.1%
2020 → 2025
10-Year CAGR—
—
—
ⓘ

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2025Latest
Diluted Shares: 63.4M
63.4M
+2.21%
FY 2024
Diluted Shares: 62.0M
62.0M
+1.10%
FY 2023
Diluted Shares: 61.3M
61.3M
+36.27%
FY 2022
Diluted Shares: 45.0M
45.0M
+27.23%
FY 2021
Diluted Shares: 35.4M
35.4M
+39.47%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs FULC
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+>999%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+>999%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+>999%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+>999%
#5
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M+>999%
#6
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M+>999%
#7
Fulcrum Therapeutics, Inc.FULC
Fulcrum Therapeutics, Inc.YOU
63.4M—

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

Fulcrum Therapeutics, Inc. (FULC) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2025, Fulcrum Therapeutics, Inc. reports 63.4M basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

Fulcrum Therapeutics, Inc.'s basic shares outstanding (63.4M) represents currently issued shares. Diluted shares outstanding (63.4M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.00%.

Shares Outstanding vs. Float (Free Float)

Fulcrum Therapeutics, Inc.'s float is 48.0M (88.7% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float48.0M(88.7%)
Outstanding54.1M

ⓘ Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · USD

About shares outstanding & methodology

Fulcrum Therapeutics, Inc. (FULC) shares outstanding history from 2017 to 2025. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

Fulcrum Therapeutics, Inc. shares outstanding for the fiscal year ending December 31, 2025 were 63.4M, a 2.21% increase year-over-year. Fulcrum Therapeutics, Inc. FY 2025 shares outstanding were 63.4M, a +2.21% increase from FY 2024.

Fulcrum Therapeutics, Inc. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of — — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.
Market capSplitsEarningsFinancials (Income)Cash on handFree cash flowNet incomePrice history

Frequently asked questions

FULC shares outstanding · 4 questions

As of December 31, 2025, Fulcrum Therapeutics, Inc. (FULC) has approximately 63.4M basic shares outstanding and 63.4M diluted shares outstanding. This represents a +2.21% year-over-year increase from FY 2024 (62.0M). The increase may reflect equity compensation issuances or secondary offerings.

FULC shares outstandinghow many shares does FULC haveFULC basic shares 2025FULC diluted shares

▸ Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · Fulcrum Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-09